Inside Health Policy, November 10, 2025: Inside Health Policy describes controversy about FDA “Expert Panels” and quotes NCHR Diana Zuckerman on why these panels have conflicts of interest and eliminating menopausal hormone therapy black box warnings about cancer and heart disease is a mistake.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
US to remove warnings from menopause hormone therapy
AFP News, November 11, 2025: France 24 explains FDA decision to delete most black box warnings for hormone therapy for menopause, despite controversies about the risks. NCHR’s Diana Zuckerman says warnings needed to be updated but hormones have serious risks and limited benefits.
Read More »Politico Prescription Plus: FDA Removes Black Box HRT Warning
Politico, November 11, 2025: FDA Commissioner Marty Makary announces that FDA seeks eliminating most black box warnings from hormone therapy for menopause and accuses “dogma” that scared women. NCHR Diana Zuckerman said risks of cancer and heart disease are well established and claims of incomparable benefits are PR rather than science.
Read More »The FDA removes long-standing warning from hormone-based menopause drugs
AP News, November 10, 2025: AP explains FDA decision to
delete most black box warnings for hormone therapy for menopause,
despite controversies about the risks. NCHR’s Diana Zuckerman
says FDA lost credibility for deleting such important warnings without
scientific review using FDA Advisory Committee.
F.D.A. Will Remove Black Box Warnings From Hormone Treatments for Menopause
The New York Times, November 10, 2025: This NYT article describes the different data and opinions regarding FDA Commissioner Makary’s decision to remove the black box from all hormone therapy products for menopause despite risks of cancer and stroke. NCHR president Dr. Diana Zuckerman explains why this is a step backward for women’s health.
Read More »